Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US
Fewer than half of included patients with aOC received 1LM treatment in the real-world setting. More work is needed to understand reasons underlying real-world 1LM treatment choice for patients with aOC.
Authors
- Megha Dayma
- Dana M. Chase (ORCID: https://orcid.org/0000-0002-1073-8688)
- Monica Kobayashi
- Linda Kalilani
- Jeanne M. Schilder (ORCID: https://orcid.org/0000-0002-6322-5376)
- Elif Coskuncay
- Zsófia Kiss (ORCID: https://orcid.org/0000-0002-8395-1949)
- Amanda Golembesky
- Maureen Cooney
Institutions
- University of California, Los Angeles (US)
- GlaxoSmithKline (India) (IN)
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline (Germany) (DE)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1080/14796694.2025.2526273
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- GlaxoSmithKline